ArticleBritish journal of haematology2026

A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.

Georg Heß et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.